The Checkpoint Inhibitor Refractory Cancer market has rapidly evolved, driven by innovative therapies addressing resistance in cancer patients. This specialized segment reflects significant shifts in oncology treatment dynamics, underpinned by advances in immunotherapy and increasing demand for effective cancer relapse management solutions. Market players are aggressively exploring new avenues...